OBJECTIVE. significantly different classification rates of patients. These differences were even larger when using fixed %fpsa thresholds.
|
|
- Elvin Lang
- 5 years ago
- Views:
Transcription
1 Original Article CLINICAL IMPACT OF DIFFERENT PSA ASSAYS STEPHAN et al. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies Carsten Stephan, Jürgen Kramer, Hellmuth-Alexander Meyer, Glen Kristiansen*, Sabine Ziemer, Serdar Deger, Michael Lein, Stefan A. Loening and Klaus Jung Departments of Urology, *Pathology, and Clinical Chemistry and Laboratory Medicine, Charité Universitätsmedizin Berlin, CCM, Germany Accepted for publication 21 December 2006 CS and JK contributed equally to this work. All authors are members of the Biomarkers of Prostate Cancer Group, CCM OBJECTIVE To show the effect of different results for total prostate specific antigen (tpsa) and percentage free/total PSA (%fpsa) obtained with different assays for differentiating between benign and malignant prostate diseases. PATIENTS AND METHODS Data were used for tpsa and fpsa levels from 596 patients with prostate cancer (314) or no evidence of cancer (282) within the PSA range ng/ml, analysed with assays from Abbott (AxSYM), Beckman Coulter (Access), DPC (Immulite 2000), and Roche (Elecsys 2010), and with tpsa and complexed PSA (cpsa) assays from Bayer (ADVIA Centaur), as already reported. Receiver operating characteristics (ROC), specificities at assaydependent and fixed thresholds, and the percentages of correct classification rates of patients were calculated. RESULTS Whereas the areas under the ROC curves were no different among all tpsa assays, the assayspecific thresholds at 90% sensitivity were ng/ml. When using fixed 2.5 or 4 ng/ ml tpsa thresholds there was a wide sensitivity range, with significant differences among almost all assays, resulting in significantly different classification rates of patients. These differences were even larger when using fixed %fpsa thresholds. CONCLUSIONS The current situation of differences among PSA values measured with different assays do not allow the recommendation of uniform PSA limits as biopsy criteria. For that purpose, better harmonization of PSA values between the different PSA test systems must be realized. KEYWORDS PSA, prostate cancer, assays, variation INTRODUCTION PSA is accepted as adding significant information for the early detection of prostate cancer, but the low positive predictive value and the low specificity are major drawbacks with this marker [1]. The use of molecular forms of PSA such as free PSA (fpsa) and its ratio to total PSA (%fpsa) or complexed PSA (cpsa) has been proposed to enhance the diagnostic specificity for detecting prostate cancer [2,3]. However, tpsa and especially fpsa concentrations obtained with different assays are very discordant [4]. These assay-dependent variations could result in misinterpretations of individual tpsa and %fpsa values, with possibly erroneous clinical decisions for detecting prostate cancer. Non-uniform calibration of the assays and nonequimolar detection of tpsa were suggested to be the essential reasons for this discordance [5,6]. Consequently, PSA reference materials were developed [7]. Promising efforts have been made in adjusting PSA calibrations using the WHO PSA reference materials and with the introduction of equimolar-response assays [8,9]. The USA Food and Drug Administration approval of %fpsa was initially limited to the Access assay (Hybritech, Beckman Coulter, Brea, CA, USA) with extension to the Abbott (Abbott Park, IL, USA) and Roche (Roche Diagnostics Corp., Indianapolis, IN, USA) assays only recently. Although the insufficient comparability between various PSA test systems was already discussed previously [4,9,10], there are only a few studies, with few assays and few samples, that do not fully describe the current situation, especially the clinical significance [11,12]. Two recent studies were likewise solely focused on the analytical aspects without considering the diagnostic consequence [13,14]. Recently, we compared five different tpsa and fpsa assays (one with cpsa) frequently used in clinical practice in 596 sera from patients with no evidence of prostate cancer and patients with cancer, from an analytical perspective for the interchangeability of PSA values among the assays and their equimolar characteristics [15]. There was inadequate comparability of tpsa, fpsa and %fpsa values measured by the different assays [15]. In the present study the main focus was directed on the clinical impact of these assay-dependent differences in tpsa and especially %fpsa values. We evaluated the assay-related absolute thresholds at 90% and 95% sensitivity, and the impact of fixed thresholds for tpsa (2.5 and 4 ng/ml) and %fpsa (15%, 20%, 25%) on the correct classification rate when using the five different assays BJU INTERNATIONAL 99, doi: /j x x 1427
2 STEPHAN ET AL. TABLE 1 The median (95% CI) tpsa and %fpsa values, AUC and specificities at fixed tpsa and %fpsa 90% and 95% sensitivity thresholds, with the corresponding tpsa thresholds for the five tpsa and %fpsa assays, calculated from with 314 patients with prostate cancer and 282 without Assay Median, ng/ml or % AUC 90% sensitivity 95% sensitivity Threshold, ng/ml or % Specificity, % Threshold, ng/ml or % Specificity % tpsa* AxSYM 4.6 ( ) 0.72 ( ) ( ) ( ) Access 5.14 ( ) 0.70 ( ) ( ) ( ) Centaur 4.61 ( ) 0.71 ( ) ( ) ( ) Immulite 5.70 ( ) 0.71 ( ) ( ) ( ) Elecsys 5.48 ( ) 0.70 ( ) ( ) ( ) %fpsa* AxSYM 17.9 ( ) 0.80 ( ) ( ) d ( ) e Access 14.5 ( ) 0.81 ( ) c,e ( ) a,c,d ( ) e Centaur 17.7 ( ) 0.77 ( ) a,b,d ( ) b ( ) Immulite 11.4 ( ) 0.81 ( ) c ( ) b ( ) Elecsys 13.8 ( ) 0.79 ( ) b ( ) ( ) a,b *The median values of all five assays were significantly different from each other (Wilcoxon test of paired samples; P < 0.001) except for the tpsa test between AxSYM and Centaur (P = 0.212). The %fpsa for the cpsa assay was calculated as (1 cpsa/tpsa) 100. All significances for %fpsa (P < ) were Bonferroni corrected. Significantly different from: a AxSYM; b Access; c Centaur; d Immulite; e Elecsys. PATIENTS AND METHODS The study group comprised 596 untreated White men with a tpsa concentration of ng/ml, as determined with the Access PSA system (Hybritech, Beckman Coulter) for this investigation. All men were referred to our clinic, thus resulting in an over-representation of prostate cancer compared with a screening population. The patients were classified into two groups: 314 men had a histologically confirmed diagnosis of prostate cancer (median age 66 years, range 38 85) and 282 men did not (median age 63 years, range 43 79) on prostate biopsy (8 12 cores). Blood samples were taken before any diagnostic or therapeutic procedures involving the prostate, and 4 weeks after a DRE, prostatic biopsy or TRUS. The samples were collected between 2001 and 2004, and sera were stored at 80 C and analysed retrospectively. The measurements were made according to the manufacturer s instructions on the analysers AxSYM (Abbott: tpsa, cat. no. 3C19-20; fpsa, cat. no. 3C 20 20), Elecsys 2010 (Roche: tpsa, cat. no ; fpsa, cat. no ), and ADVIA Centaur (Bayer Diagnostics, Leverkusen, Germany: tpsa, cat. no ; cpsa, cat. no ), Access (Beckman Coulter: Hybritech PSA, cat. no ; Hybritech fpsa, cat. no ), and Immulite 2000 systems (Diagnostic Product Corp., Los Angeles, CA, USA; tpsa, cat. no. L2KPS6; fpsa, cat. no. L2KPF2) as already described [15]. The cpsa values were transformed into fpsa concentrations as tpsa cpsa and the %fpsa values calculated as percentage ratios of fpsa to tpsa. The between-run imprecision profiles of the measurements were estimated using control materials supplied by the manufacturers, commercial control materials, and in-house serum pools; all interassay coefficients of variation were <8% (over days). The study was carried out in accordance with ethical standards of the local ethics board and the Helsinki Declaration of 1996, including informed consent of all participants. Statistical calculations were performed with SPSS 13.0 for Windows (SPSS, Chicago, USA) and GraphPad Prism 4.03 (GraphPad Software, San Diego, USA). The diagnostic accuracy was evaluated using receiver operating characteristic (ROC) curve analysis with calculations of the area under the curve (AUC) using MedCalc (MedCalc Software, Mariakerke, Belgium). Significance levels at 95% and 90% sensitivity were calculated by using GraphROC 2.1 for Windows [16]. P < 0.05 was considered to indicate statistical significance, using the Bonferroni correction if there were multiple comparisons (10 comparisons). RESULTS The analytical data of the comparisons among the various assays using the Access Hybritech assay as the comparison method, were reported previously [15]. The main differences are shown in Table 1; the median tpsa concentrations for the five assays was ng/ml, with significant differences among the assays. These differences are also reflected by the different values at ng/ ml tpsa at a threshold of 90% sensitivity, and at ng/ml tpsa at the corresponding level of 95% sensitivity, respectively (Table 1). However, when comparing the AUC for tpsa, there was no difference among the assays (P = ). The specificities at 90% and 95% sensitivity also did not differ (P = ) among the assays (Table 1). These equivalent data for the diagnostic validity among the assays confirm that all tpsa assays are comparable in their diagnostic validity if the assay-dependent thresholds are considered. Consequently and when using fixed tpsa thresholds of 2.5 or 4 ng/ml, the number of patients with or without prostate cancer who were classified as true-positive (cancer) or truenegative (no cancer) significantly differed among the five assays (Table 2). For example, when using 4 ng/ml as the threshold, the true-positive results were different in eight of the 10 comparisons, corresponding to BJU INTERNATIONAL
3 CLINICAL IMPACT OF DIFFERENT PSA ASSAYS TABLE 2 Classification of 314 patients with and 282 without malignancy using fixed tpsa thresholds of 2.5 and 4.0 ng/ml for the five tpsa assays, and fixed %fpsa thrsholds of 15%, 20%, and 25% for the five %fpsa assay combinations Selected thresholds sensitivities of 70% (Centaur) to 85% (Immulite). N (%) of classified patients AxSYM Access Centaur Immulite Elecsys tpsa 2.5 ng/ml True positive 288 (91.7) d 288 (91.7) d 283 (90.1) d,e 297 (94.6) a,b,c 292 (93.0) c True negative 116 (41.1) b,d,e 95 (33.7) a,c 113 (40.1) b,d,e 89 (31.6) a,c 96 (34.0) a,c 4.0 ng/ml True positive 228 (72.6) b,d,e 246 (78.3) a,c,d 221 (70.4) b,d,e 268 (85.4) a,b,c,e 255 (81.2) a,c,d True negative 165 (23.0) b,d,e 143 (50.7) a,c 162 (57.4) b,d,e 138 (48.9) a,c 143 (50.7) a,c %fpsa <15% True positive 183 (58.3) b,d,e 239 (76.1) a,c,d 182 (58.0) b,d,e 279 (88.9) a,b,c,e 240 (76.4) a,c,d True negative 238 (84.4) b,d,e 203 (72.0) a,c,d,e 228 (80.9) b,d,e 141 (50.0) a,b,c,e 181 (64.2) a,b,c,d <20% True positive 256 (81.5) b,d,e 293 (93.3) a,c,d 249 (79.3) b,d,e 307 (97.8) a,b,c,e 297 (94.6) a,c,d True negative 180 (63.8) b,d,e 127 (45.0) a,c,d,e 177 (62.8) b,d,e 79 (28.0) a,b,c,e 103 (36.5) a,b,c,d <25% True positive 285 (90.8) b,d,e 305 (97.1) a,c 290 (92.4) b,d,e 310 (98.7) a,c 307 (97.8) a,c True negative 121 (42.9) b,d,e 65 (23.0) a,c,d,e 126 (44.7) b,d,e 39 (13.8) a,b,c 49 (17.4) a,b,c *Significant differences of the classifications (McNemar test of paired samples; Bonferroni corrected; P < 0.05 <0.001). Significantly different from the: a AxSYM; b Access; c Centaur; d Immulite; e Elecsys. Corresponding calculations for %fpsa obtained with the five assays showed that the median values for all assays were also significantly different from each other (Table 1). Again, these differences among the assays were also reflected by the different absolute %fpsa thresholds of % at 90% sensitivity and % at the corresponding 95% sensitivity level. However, the AUC were in a narrow range of , but with four significant differences, between the Centaur assays (0.77) and all others except the Elecsys assays (0.79), and the Access and Elecsys assays. At 90% sensitivity the specificity showed a significantly better performance for the Access compared to all other except the Elecsys assay. All other comparisons at this point showed no differences. At 95% sensitivity there were also almost no differences, except a significantly better performance of the AxSYM and Access compared to the Elecsys assay. Thus, the data for the diagnostic validity among %fpsa values were almost equivalent when assaydependent thresholds at 90% or 95% sensitivity were considered. By contrast, when using fixed %fpsa thresholds of 15%, 20% or 25%, the number of true-positive or true-negative patients correctly classified significantly differed among the five assays for most comparisons (Table 2). For example, when using a 15% threshold for %fpsa, the Immulite assays detected almost 100 more patients with cancer than the AxSYM and Centaur assays, but missed almost 100 more patients with no cancer than the AxSYM assay. These results would imply that the Immulite tests had a 30% higher sensitivity, but a 31 34% lower specificity than the two other assays. These differences were also evident at the two other fixed thresholds of 20% and 25% (Table 2). The differences in sensitivity among the assays understandably decrease and the corresponding specificities increase with higher thresholds. Thus, it is clear that fixed %fpsa thresholds lead to large differences among the assays, with a misclassification of more than a third of the patients only by using another assay. DISCUSSION Since the introduction of the assays for molecular forms of PSA in the early 1990s [2,3] and their routine clinical use there have been many reports on the use of %fpsa%fpsa to reduce the number of unnecessary prostate biopsies. Only a few studies have given enough attention to possible differences and misleading interpretation when using different assays for tpsa and fpsa [11,12,15,17]. The present study shows significant differences among five frequently used commercial tpsa and fpsa assays, although the WHO standard was introduced to improve the comparability of PSA measurement using different assays [15]. However, the present results show that the situation is unsatisfactory. An optimum tpsa threshold for the first decision to guide the patient remains of utmost importance. Whereas most clinicians still prefer the 4 ng/ ml threshold to direct the patient for a biopsy or further assessments, in the European Randomized Study for Prostate Cancer study the threshold was lowered to 3 ng/ml [18]. Moreover, the tendency, especially in the USA, is to lower the threshold to 2.5 ng/ml to keep at least 90% sensitivity [19]. This could be confirmed by the present results, but only when using the Centaur or AxSYM tpsa assays. Furthermore, the cancer detection rate at lower tpsa concentrations as analysed by Thompson et al. [20] is, especially at 2 4 ng/ml tpsa, similar to that of the grey zone of 4 10 ng/ml [21], so that the 4 ng/ml threshold loses any utility. However, it is surprising that these controversial discussions do not consider sufficiently the inadequate interchangeability of PSA values obtained with different assays, as shown in the present study. The misclassifications shown in Table 2 if fixed thresholds are used, or a tpsa level of ng/ml to reach 90% sensitivity (Table 1), clearly underline this issue. One possible explanation for the large variety among the five assays might be that only three (AxSYM, Centaur, Elecsys) are calibrated against the WHO standard [22]. The tpsa assays from Beckman and DPC, not calibrated against the WHO standard, tended to give generally higher tpsa concentrations. However, despite the uniform calibration against the WHO standard, the Elecsys assay resulted in higher values than the other two WHO calibrated assays (AxSYM and Centaur). Thus, calibration might be an important, but not the exclusive factor, to improve the harmonization among the various assays. The situation seems to be similar when analysing the calculated %fpsa; here the 2007 BJU INTERNATIONAL 1429
4 STEPHAN ET AL. assays not calibrated against WHO standards show the lowest (DPC) and third lowest values (Beckman), with a range for the median %fpsa of % and significant differences among all median values (Table 1). However, the use of fixed thresholds for %fpsa (15%, 20%, 25%) gave larger problems than for tpsa, as shown by the misclassifications in Table 2. This is important from the clinical perspective, as the fpsa assays used should be given more attention as additional tools to reduce unnecessary prostate biopsies [23]. At 95% sensitivity, the respective absolute %fpsa thresholds varied from 18% to 28%, so that only assay-specific thresholds would give comparable clinical results. However, it is also obvious that the WHO calibration, used according to the information from the manufacturers of the AxSYM and Elecsys assays, does not guarantee a solution for the poor interchangeability of %fpsa results (Table 1). Medians and thresholds at 90% and 95% sensitivity were clearly different. These thresholds can only be regarded for comparative purposes and not as practical thresholds, because the patients included in the present study were not from a screening population. In conclusion, in this study with parallel measurements of five current tpsa and fpsa assays in almost 600 patients, within the relevant tpsa range, showed highly significant differences for tpsa and especially %fpsa. These differences were also obtained with assays calibrated using the WHO standard. Thus, we think that a better harmonization of PSA results among different assays is needed as an essential precondition for success when selecting final recommendations for tpsa or %fpsa thresholds as indicators for biopsy. Further investigations on the reference material or a prospective reference method, with a final aim of traceability for all tpsa and fpsa assays used, are needed to improve this difficult situation for clinicians. Currently, the use of different tpsa and fpsa assays with fixed thresholds leads to serious problems and large differences when deciding to take a prostate biopsy or not. ACKNOWLEDGEMENTS We especially thank Janett Reiche for her valuable technical assistance. This work was supported by the Deutsche Krebshilfe (Grant ST1), ProFIT (No ) the Berliner Sparkassenstiftung Medizin, and by the SONNENFELD-Stiftung. CONFLICT OF INTEREST None declared. REFERENCES 1 Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery what we have learned and where we are going. J Urol 1999; 162: Lilja H, Christensson A, Dahlen U et al. Prostate-specific antigen in serum occurs predominantly in complex with α1- antichymotrypsin. Clin Chem 1991; 37: Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: Semjonow A, De Angelis G, Oberpenning F, Schmid HP, Brandt B, Hertle L. The clinical impact of different assays for prostate specific antigen. BJU Int 2000; 86: Blijenberg BG, Yurdakul G, Van Zelst BD, Bangma CH, Wildhagen MF, Schroder FH. Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancer. BJU Int 2001; 88: Semjonow A, Oberpenning F, Brandt B, Zechel C, Brandau W, Hertle L. Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen. Urology 1996; 48 (Suppl.): Stamey TA, Chen Z, Prestigiacomo AF. Reference material for PSA: the IFCC standardization study. International Federation of Clinical Chemistry. Clin Biochem 1998; 31: Rafferty B, Rigsby P, Rose M, Stamey T, Gaines Das R. Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90: 10). Clin Chem 2000; 46: Semjonow A, Oberpenning F, Weining C et al. Do modifications of nonequimolar assays for total prostate-specific antigen improve detection of prostate cancer? Clin Chem 2001; 47: Semjonow A, Brandt B, Oberpenning F, Roth S, Hertle L. Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values. Prostate Suppl 1996; 7: Link RE, Shariat SF, Nguyen CV et al. Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening. J Urol 2004; 171: Patel D, White PA, Milford WA. A comparison of six commercial assays for total and free prostate specific antigen (PSA): the predictive value of the ratio of free to total PSA. BJU Int 2000; 85: Kort SA, Martens F, Vanpoucke H, van Duijnhoven HL, Blankenstein MA. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. Clin Chem 2006; 52: Roddam AW, Rimmer J, Nickerson C, Ward AM; NHS Prostate Cancer Risk Management Programme. Prostatespecific antigen: bias and molarity of commercial assays for PSA in use in England. Ann Clin Biochem 2006; 43: Stephan C, Klaas M, Muller C, Schnorr D, Loening SA, Jung K. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem 2006; 52: Kairisto V, Poola A. Software for illustrative presentation of basic clinical characteristics of laboratory tests GraphROC for Windows. Scand J Clin Lab Invest Suppl 1995; 222: Jung K, Stephan C, Lein M et al. Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem 1996; 42: Schröder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol 2000; 163: BJU INTERNATIONAL
5 CLINICAL IMPACT OF DIFFERENT PSA ASSAYS 19 Catalona WJ, Partin AW, Finlay JA et al. Use of percentage of free prostatespecific antigen to identify men at high risk of prostate cancer when PSA levels are ng/ml and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 1999; 54: Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350: Catalona WJ, Richie JP, Ahmann FR et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 1994; 151: Stephan C, Semjonow A. Accuracy assessment of PSA methods must be based on clinical instead of artificial samples a response to AW Roddam et al. Ann Clin Biochem 2006; 43: Ann Clin Biochem 2006; 43: Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: Correspondence: Carsten Stephan, Department of Urology, Charité Universitätsmedizin Berlin, CCM, Charitéplatz 1, D Berlin, Germany. carsten.stephan@charite.de Abbreviations: ROC, receiver operating characteristic (curve); AUC, area under ROC curve; fpsa, free PSA; tpsa, total PSA; cpsa, complexed PSA; PSA, prostate specific antigen; %fpsa, percent free PSA BJU INTERNATIONAL 1431
Intermethod Differences in Results for Total PSA, Free PSA, and Percentage of Free PSA
Clinical Chemistry / PSA and Free PSA Method Differences Intermethod Differences in Results for Total PSA, Free PSA, and Percentage of Free PSA Patricia R. Slev, PhD, Sonia L. La ulu, and William L. Roberts,
More informationBetween-Method Differences in Prostate-Specific Antigen Assays Affect Prostate Cancer Risk Prediction by Nomograms
Clinical Chemistry 57:7 995 1004 (2011) Cancer Diagnostics Between-Method Differences in Prostate-Specific Antigen Assays Affect Prostate Cancer Risk Prediction by Nomograms Carsten Stephan, 1,2* Kerstin
More informationAssay-speciWc artiwcial neural networks for Wve diverent PSA assays and populations with PSA 2 10 ng/ml in 4,480 men
World J Urol (2007) 25:95 103 DOI 10.1007/s00345-006-0132-9 ORIGINAL ARTICLE Assay-speciWc artiwcial neural networks for Wve diverent PSA assays and populations with PSA 2 10 ng/ml in 4,480 men Carsten
More informationResearch Article External Validation of an Artificial Neural Network and Two Nomograms for Prostate Cancer Detection
International Scholarly Research Network ISRN Urology Volume 2012, Article ID 643181, 6 pages doi:10.5402/2012/643181 Research Article External Validation of an Artificial Neural Network and Two Nomograms
More informationComplexed Prostate-specific Antigen for the Detection of Prostate Cancer
Complexed Prostate-specific Antigen for the Detection of Prostate Cancer XAVIER FILELLA 1, DAVID TRUAN 2, JOAN ALCOVER 2, RAFAEL GUTIERREZ 2, RAFAEL MOLINA 1, FRANCISCA COCA 1 and ANTONIO M. BALLESTA 1
More informationUse of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease
Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate From Benign Prostatic Disease A Prospective Multicenter Clinical Trial William J. Catalona, MD; Alan W. Partin,
More informationPro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer
REVIEW Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer Stephen D. Mikolajczyk and Harry G. Rittenhouse Beckman Coulter, Inc., San Diego, CA,
More informationIntroduction. Objective To investigate the clinical significance of the 1.13 ng/ml, P<0.001) and a lower free-to-total PSA
British Journal of Urology (1998), 81, 532 538 Free-to-total prostate-specific antigen (PSA) ratio improves the specificity for detecting prostate cancer in patients with prostatism and intermediate PSA
More informationEnzyme Immunoassay for the Quantitative Determination of Free Prostate Specific Antigen (f-psa) in Human Serum
Enzyme Immunoassay for the Quantitative Determination of Free Prostate Specific Antigen (f-psa) in Human Serum FOR RESEARCH USE ONLY Store at 2 to 8 C. PROPRIETARY AND COMMON NAMES f-psa Enzyme Immunoassay
More informationDetermination of An Optimum Cut-off Point for % fpsa/tpsa to Improve Detection of Prostate Cancer
Original Article DOI: 10.21276/APALM.1254 Determination of An Optimum Cut-off Point for % fpsa/tpsa to Improve Detection of Prostate Cancer Vineeth* G Nair and M. H. Shariff Department of Pathology, Yenepoya
More informationAlthough the test that measures total prostate-specific antigen (PSA) has been
ORIGINAL ARTICLE STEPHEN LIEBERMAN, MD Chief of Urology Kaiser Permanente Northwest Region Clackamas, OR Effective Clinical Practice. 1999;2:266 271 Can Percent Free Prostate-Specific Antigen Reduce the
More informationDistribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer
Urological Oncology CHUN et al. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer Felix K.-H. Chun, Georg C.
More informationFocus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer
Focus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer Prostate Cancer in Ireland & Worldwide In Ireland, prostate cancer
More information10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION
THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION Lenette Walters, MS, MT(ASCP) Medical Affairs Manager Beckman Coulter, Inc. *phi is a calculation using the values from PSA, fpsa and p2psa
More informationCumulative Prostate Cancer Risk Assessment with the Aid of the Free-to-Total Prostate Specific Antigen Ratio
European Urology European Urology 45 (2004) 160 165 Cumulative Prostate Cancer Risk Assessment with the Aid of the Free-to-Total Prostate Specific Antigen Ratio Gunnar Aus a,*, Charlotte Becker b, Stefan
More informationInt. J. Cancer: 111, (2004) 2004 Wiley-Liss, Inc.
Int. J. Cancer: 111, 310 315 (2004) 2004 Wiley-Liss, Inc. Publication of the International Union Against Cancer ALGORITHMS BASED ON PROSTATE-SPECIFIC ANTIGEN (PSA), FREE PSA, DIGITAL RECTAL EXAMINATION
More informationUse of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer {
Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer { (2003) 6, 39 44 ß 2003 Nature Publishing Group All rights reserved 1365 7852/03 $25.00 www.nature.com/pcan
More informationContribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate volume matter?
ORIGINAL ARTICLE Gulhane Med J 2018;60: 14-18 Gülhane Faculty of Medicine 2018 doi: 10.26657/gulhane.00010 Contribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate
More informationTable 1. Descriptive characteristics, total prostate-specific antigen, and percentage of free/total prostate-specific antigen distribution Age Groups
Oncology Population-based Analysis of Normal Total PSA and Percentage of Free/Total PSA Values: Results From Screening Cohort Umberto Capitanio, Paul Perrotte, Laurent Zini, Nazareno Suardi, Elie Antebi,
More informationCASE STUDY 3: PSA-STANDARDISATION & VARIABILITY COMPARATIVE STUDY IN HOSPITALS
CASE STUDY 3: PSA-STANDARDISATION & VARIABILITY COMPARATIVE STUDY IN HOSPITALS Dr Ophelia Blake FRCPath University Hospital Limerick, IRELAND JCTLM Meeting BIPM, Sevres,France 4 th December 2013 Prostate
More informationKEY WORDS : Total Prostate Specific Antigen, Prostatic Acid Phosphatase, Benign Prostatic Hyperplasia, Prostate Cancer, and Sudanese.
International Journal of Pharmaceutical Science Invention ISSN (Online): 2319 6718, ISSN (Print): 2319 670X Volume 3 Issue 1 January 2014 PP.36-40 Serum Total Prostatic Specific Antigen and Prostatic Acid
More informationPSA and the Future. Axel Heidenreich, Department of Urology
PSA and the Future Axel Heidenreich, Department of Urology PSA and Prostate Cancer EAU Guideline 2011 PSA is a continuous variable PSA value (ng/ml) risk of PCa, % 0 0.5 6.6 0.6 1 10.1 1.1 2 17.0 2.1 3
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationBPH AND BEYOND. BPSA: A Novel Serum Marker for Benign Prostatic Hyperplasia Kevin M. Slawin, MD, Shahrokh Shariat, MD, Eduardo Canto, MD
BPH AND BEYOND B: A Novel Serum Marker for Benign Prostatic Hyperplasia Kevin M. Slawin, MD, Shahrokh Shariat, MD, Eduardo Canto, MD Baylor Prostate Center, The Scott Department of Urology, Baylor College
More informationAmbulatory and Office Urology Optimal Measure of PSA Kinetics to Identify Prostate Cancer
Ambulatory and Office Urology Optimal Measure of PSA Kinetics to Identify Prostate Cancer Luigi Benecchi, Anna Maria Pieri, Carmelo Destro Pastizzaro, and Michele Potenzoni OBJECTIVES METHODS RESULTS CONCLUSIONS
More informationRole of Prostate-Specific Antigen Change Ratio at Initial Biopsy as a Novel Decision-Making Marker for Repeat Prostate Biopsy
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53..46 Urological Oncology Role of Prostate-Specific Antigen Change Ratio at Initial Biopsy as a Novel Decision-Making Marker for Repeat Prostate Biopsy
More informationBJUI. Study Type Prognosis (individual cohort study) Level of Evidence 2b OBJECTIVES CONCLUSIONS
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTING THE OUTCOME OF PROSTATE BIOPSY HERNANDEZ et al. BJUI BJU INTERNATIONAL Predicting the outcome of prostate biopsy: comparison
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationMulticenter Comparison of Four Automated Immunoassay Analyzers for Prostate Specific Antigen
Letter to the Editor Clinical Chemistry Ann Lab Med 19;39:6-41 https://doi.org/1.3343/alm.19.39.4.6 ISSN 2234-36 eissn 2234-3814 Multicenter Comparison of Four Automated Immunoassay Analyzers for Prostate
More informationMulticenter Evaluation of [ 2]Proprostate-Specific Antigen and the Prostate Health Index for Detecting Prostate Cancer
Papers in Press. Published December 4, 2012 as doi:10.1373/clinchem.2012.195784 The latest version is at http://hwmaint.clinchem.org/cgi/doi/10.1373/clinchem.2012.195784 Clinical Chemistry 59:1 000 000
More informationAge-specific reference levels of serum prostate-specific antigen and prostate volume in healthy Arab men
Original Article KEHINDE et al. Age-specific reference levels of serum prostate-specific antigen and prostate volume in healthy Arab men ELIJAH O. KEHINDE, OLUSEGUN A. MOJIMINIYI*, MEHRAJ SHEIKH, KALEEL
More informationPSA Isoforms in Prostate Cancer Detection
european urology supplements 5 (2006) 495 499 available at www.sciencedirect.com journal homepage: www.europeanurology.com PSA Isoforms in Prostate Cancer Detection Haluk Özen a, *, Sinan Sözen b a Department
More informationMARTIN FLEISHER, PH.D., FACB MEMORIAL SLOAN-KETTERING CANCER CENTER NEW YORK, N.Y.
MARTIN FLEISHER, PH.D., FACB MEMORIAL SLOAN-KETTERING CANCER CENTER NEW YORK, N.Y. FLEISHEM@MSKCC.ORG The Ideal Tumor Marker Quantitative level of TM reflects tumor burden with high diagnostic sensitivity
More informationEUROPEAN UROLOGY 58 (2010)
EUROPEAN UROLOGY 58 (2010) 551 558 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Prostate Cancer Prevention Trial and European Randomized Study of Screening
More informationAge-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients
(2003) 6, 256 260 & 2003 Nature Publishing Group All rights reserved 1365-7852/03 $25.00 www.nature.com/pcan Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients 1, *
More informationDevelopment and Internal Validation of a Prostate Health Index Based Nomogram for Predicting Prostate Cancer at Extended Biopsy
Development and Internal Validation of a Prostate Health Index Based Nomogram for Predicting Prostate Cancer at Extended Biopsy Giovanni Lughezzani,*, Massimo Lazzeri, Alessandro Larcher, Giuliana Lista,
More informationDeveloping a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection
DOI 10.1186/s40064-016-3176-3 RESEARCH Open Access Developing a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection Yuxiao Zheng, Yuan Huang, Gong
More informationRepeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA?
Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA? Connolly, D., Black, A., Murray, L., Nambirajan, T., Keane, P. F., & Gavin, A. (2009). Repeating an abnormal
More informationUtility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma
Disease Markers 19 (2003,2004) 287 292 287 IOS Press Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma V. Thakur a,, P.P. Singh b, M. Talwar c and U. Mukherjee
More informationPREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
More informationThe prostate health index PHI predicts oncological outcome and biochemical recurrence after radical prostatectomy - analysis in 437 patients
/, 2017, Vol. 8, (No. 45), pp: 79279-79288 The prostate health index PHI predicts oncological outcome and biochemical recurrence after radical prostatectomy - analysis in 437 patients Andreas Maxeiner
More informationPapers in Press. First published October 7, 2004 as doi: /clinchem
Papers in Press. First published October 7, 2004 as doi:10.1373/clinchem.2004.040469 Clinical Chemistry 50:12 000 000 (2004) Proteomics and Protein Markers Analysis of Subforms of Free Prostate-Specific
More informationNEURO-FUZZY SYSTEM FOR PROSTATE CANCER DIAGNOSIS LUIGI BENECCHI
ADULT UROLOGY NEURO-FUZZY SYSTEM FOR PROSTATE CANCER DIAGNOSIS LUIGI BENECCHI ABSTRACT Objectives. To develop a neuro-fuzzy system to predict the presence of prostate cancer. Neuro-fuzzy systems harness
More informationClinical Significance of Measuring Prostate- Specific Antigen
Clinical Significance of Measuring Prostate- Specific Antigen Borros M. Arneth, MS, MD (Institute of Clinical Chemistry and Laboratory Medicine, Johannes Gutenberg University Mainz, Mainz, Germany) DOI:
More informationProstate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer: Part 1
Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer: Part 1 Review Article [1] August 01, 2002 By Alan W. Partin, MD, PhD [2], Gerald E. Hanks, MD [3], Eric A. Klein, MD [4], Judd
More informationRational Approach to Implementation of Prostate Cancer Antigen 3 Into Clinical Care
Rational Approach to Implementation of Prostate Cancer Antigen 3 Into Clinical Care Rou Wang, MD 1 ; Arul M. Chinnaiyan, MD 1,2,3 ; Rodney L. Dunn, MS 1 ; Kirk J. Wojno, MD 2 ; and John T. Wei, MD, MS
More informationPROSTATE CANCER SCREENING: AN UPDATE
PROSTATE CANCER SCREENING: AN UPDATE William G. Nelson, M.D., Ph.D. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins American Association for Cancer Research William G. Nelson, M.D., Ph.D. Disclosures
More informationProstate Cancer Screening: Risks and Benefits across the Ages
Prostate Cancer Screening: Risks and Benefits across the Ages 7 th Annual Symposium on Men s Health Continuing Progress: New Gains, New Challenges June 10, 2009 Michael J. Barry, MD General Medicine Unit
More information4/20/2015. Serum Protein Tumor Marker Assays: A Need for Constant Vigilance. Learning Objectives. Estimated Cancer Deaths in the US in 2015
Serum Protein Tumor Marker Assays: A Need for Constant Vigilance Nichole Korpi-Steiner, PhD, DABCC, FACB University of North Carolina Chapel Hill, NC Learning Objectives Describe what comprises an ideal
More informationOriginal Article. Introduction. Xin LIU 1, *Jie TANG 2, Xiang FEI 2, Qiu-Yang LI 2
Original Article Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less Xin LIU 1, *Jie TANG 2, Xiang
More information#1 cancer. #2 killer. Boulder has higher rate of prostate cancer compared to other areas surrounding Rocky Flats
Prostate cancer is a VERY COMMON DISEASE BREAKTHROUGHS IN THE DETECTION OF PROSTATE CANCER Carolyn M. Fronczak M.D., M.S.P.H. Urologic Surgery 303-647-9129 #1 cancer #2 killer Ca Cancer J Clin 2018;68:7
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationComparative Assessment of Urinary Prostate Cancer
Papers in Press. Published December 4, 2012 as doi:10.1373/clinchem.2012.195560 The latest version is at http://hwmaint.clinchem.org/cgi/doi/10.1373/clinchem.2012.195560 Clinical Chemistry 59:1 000 000
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationA pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy
ONCOLOGY LETTERS 3: 819-824, 2012 A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy ANTONINO SOTTILE 1, CINZIA ORTEGA 2, ALFREDO BERRUTI
More informationSERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA AND CANCER OF PROSTATE. A. AMAYO and W.
22 EAST AFRICAN MEDICAL JOURNAL January 2004 The East African Medical Journal Vol. 81 No. 1 January 2004 SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA AND CANCER OF PROSTATE.
More informationEffect of Verification Bias on Screening for Prostate Cancer by Measurement of Prostate-Specific Antigen
The new england journal of medicine original article Effect of Verification Bias on Screening for Prostate Cancer by Measurement of Prostate-Specific Antigen Rinaa S. Punglia, M.D., M.P.H., Anthony V.
More informationeuropean urology 55 (2009)
european urology 55 (2009) 385 393 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Is Prostate-Specific Antigen Velocity Selective for Clinically Significant
More informationPathology Consultation on Prostate-Specific Antigen Testing
Pathology Consultation on Prostate-Specific Antigen Testing Jaime H. Noguez, PhD, and Corinne R. Fantz, PhD From the Department of Pathology and Laboratory Medicine, Emory University School of Medicine,
More informationCigna Medical Coverage Policy
Cigna Medical Coverage Policy Subject Prostate-Specific Antigen (PSA) Screening for Prostate Cancer Table of Contents Coverage Policy... 1 General Background... 1 Coding/Billing Information... 12 References...
More informationReceiver operating characteristics of the prostate specific antigen test in an unselected population
102 ORIGINAL ARTICLE Receiver operating characteristics of the prostate specific antigen test in an unselected population David J McLernon, Peter T Donnan, Mike Gray, David Weller and Frank Sullivan...
More informationEuropean Urology 48 (2005)
European Urology European Urology 48 (2005) 386 399 ReviewöProstate Cancer Use of Prostate-Specific Antigen (PSA) Isoforms for the Detection of Prostate Cancer in Men with a PSA Level of 2^10 ng/ml: Systematic
More informationProstate-Specific Antigen (PSA) Test
Prostate-Specific Antigen (PSA) Test What is the PSA test? Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the
More informationAge Specific Reference Levels of Serum. Volume and Prostate Specific Antigen. Density in Healthy Iranian Men
ISSN 1735-1383 Iran. J. Immunol. March 2009, 6 (1), 40-48 Abdol Aziz Khezri, Mehdi Shirazi, Seyyed Mohammad Taghi Ayatollahi, Mehrzad Lotfi, Mehrdad Askarian, Ali Ariafar, Mohammad Amin Afrasiabi Age Specific
More informationPerformance Characteristics of Eight Estradiol Immunoassays
Clinical Chemistry / EVALUATION OF EIGHT ESTRADIOL IMMUNOASSAYS Performance Characteristics of Eight Estradiol Immunoassays David T. Yang, MD, 1 William E. Owen, MT(ASCP), 2 Carol S. Ramsay, 3 Hui Xie,
More informationDAFTAR KEPUSTAKAAN. Universitas Sumatera Utara
DAFTAR KEPUSTAKAAN Aaron Caplan: Prostate-Specific Antigen and the Early Diagnosis of Prostate Cancer: Pathology Patterns Reviews. Am J Clin Pathol 2002. Amer. Cancer Soc., Cancer Facts and Figures 2005
More informationProstate-Specific Antigen (PSA) Screening for Prostate Cancer
Medical Coverage Policy Effective Date... 4/15/2018 Next Review Date... 4/15/2019 Coverage Policy Number... 0215 Prostate-Specific Antigen (PSA) Screening for Prostate Cancer Table of Contents Related
More informationNew Markers and Multivariate Models for Prostate Cancer Detection
Review New Markers and Multivariate Models for Prostate Cancer Detection CARSTEN STEPHAN 1, HARRY RITTENHOUSE 3, HENNING CAMMANN 2, MICHAEL LEIN 1,4, MARK SCHRADER 1, SERDAR DEGER 1, KURT MILLER 1 and
More informationNIH Public Access Author Manuscript Can J Urol. Author manuscript; available in PMC 2009 September 14.
NIH Public Access Author Manuscript Published in final edited form as: Can J Urol. 2008 December ; 15(6): 4363 4374. Screening for Prostate Cancer: An Update Shahrokh F. Shariat 1, Peter T. Scardino 1,
More informationProstate Cancer Screening Guidelines in 2017
Prostate Cancer Screening Guidelines in 2017 Pocharapong Jenjitranant, M.D. Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital Prostate Specific Antigen (PSA) Prostate
More informationDepartment of Urology, II Clinic, Ankara Numune Education and Research Hospital, Ankara, Turkey 2
International Scholarly Research Network ISRN Urology Volume 2012, Article ID 252846, 5 pages doi:10.5402/2012/252846 Clinical Study The Correlation between Diffusion-Weighted Imaging and Histopathological
More informationWhat to Do with an Abnormal PSA Test. Feinberg School of Medicine, Chicago, Illinois, USA
The Oncologist Genitourinary Cancer What to Do with an Abnormal PSA Test STACY LOEB, a WILLIAM J. CATALONA b a Department of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA; b The Northwestern
More informationPSA screening. To screen or not to screen, that s the question Walid Shahrour FRCSC, MDCM, BSc Assistant professor Northern Ontario School of Medicine
PSA screening To screen or not to screen, that s the question Walid Shahrour FRCSC, MDCM, BSc Assistant professor Northern Ontario School of Medicine Conflict of Interest Declaration: Nothing to Disclose
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our
More informationPredicting Prostate Biopsy Outcome Using a PCA3-based Nomogram in a Polish Cohort
Predicting Prostate Biopsy Outcome Using a PCA3-based Nomogram in a Polish Cohort MACIEJ SALAGIERSKI 1, PETER MULDERS 2 and JACK A. SCHALKEN 2 1 Urology Department, Medical University of Łódź, Poland;
More informationSubject Review. Percent Free Prostate-Specific Antigen: Entering a New Era in the Detection of Prostate Cancer
Subject Review Percent Free Prostate-Specific Antigen: Entering a New Era in the Detection of Prostate Cancer ApOORVA R. VASHI, M.D., AND JOSEPH E. OESTERLING, M.D. The introduction of prostate-specific
More informationPCa Commentary. Executive Summary: The "PCa risk increased directly with increasing phi values."
1101 Madison Street Suite 1101 Seattle, WA 98104 P 206-215-2490 www.seattleprostate.com PCa Commentary Volume 77 September October 2012 CONTENT Page The Prostate 1 Health Index Active Surveillance 2 A
More informationProstate-Specific Antigen in 2006: Effective Use in Benign Prostatic Hyperplasia and Prostate Cancer
Volume 1, Number 3 ISSN: 1932-9245 Weill Medical College of Cornell University Reports on Men s Urologic Health 1 Editor: Steven A. Kaplan, MD, Professor of Urology, and Chief, Institute for Bladder and
More informationThe Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial Negative Biopsy
Research Article TheScientificWorldJOURNAL (2009) 9, 343 348 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2009.47 The Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial
More informationACCESS hstni SCIENTIFIC LITERATURE
ACCESS hstni SCIENTIFIC LITERATURE 2017 2018 Table of contents Performance Evaluation of Access hstni A critical evaluation of the Beckman Coulter Access hstni: Analytical performance, reference interval
More informationNew York State Soluble Tumor Markers Proficiency Test
ADREW M. CUOMO Governor October 5, 2016 HOWARD A. ZUCKER, M.D., J.D. Commissioner SALLY DRESLI, M.S., R.. Executive Deputy Commissioner ew York State Soluble Tumor Markers Proficiency Test 9-2016 1 Dear
More informationDetection of prostate cancer by MR-ultrasound fusion guided biopsy
Detection of prostate cancer by MR-ultrasound fusion guided biopsy Poster No.: C-0761 Congress: ECR 2014 Type: Scientific Exhibit Authors: T. Durmus, C. Stephan, T. Slowinski, A. Thomas, A. Maxeiner, B.
More informationUrological Society of Australia and New Zealand PSA Testing Policy 2009
Executive summary Urological Society of Australia and New Zealand PSA Testing Policy 2009 1. Prostate cancer is a major health problem and is the second leading cause of male cancer deaths in Australia
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationComparison of Five Automated Serum and Whole Blood Folate Assays
Clinical Chemistry / FIVE AUTOMATED FOLATE ASSAYS Comparison of Five Automated Serum and Whole Blood Folate Assays William E. Owen, MT(ASCP), 1 and William L. Roberts, MD, PhD 2 Key Words: Hemolysate;
More informationEvaluation of [ 2] propsa and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis
DOI 10.1515/cclm-2012-0410 Clin Chem Lab Med 2012; aop Review Xavier Filella * and Nuria Giménez Evaluation of [ 2] propsa and Prostate Health Index (phi) for the detection of prostate cancer: a systematic
More informationObjectives. Patients and Methods. Results
Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2psa) and its derivatives, %p2psa and the prostate health index (PHI), in men with a family history of prostate cancer: results
More informationProtein Biomarkers for Screening, Detection, and/or Management of Prostate Cancer
Medical Policy Manual Laboratory, Policy No. 69 Protein Biomarkers for Screening, Detection, and/or Management of Prostate Cancer Next Review: October 2018 Last Review: December 2017 Effective: January
More informationPROSTATE CANCER SURVEILLANCE
PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare
More informationPractice Patterns of Korean Urologists for Screening and Managing Prostate Cancer according to PSA Level
Original Article http://dx.doi.org/10.3349/ymj.2012.53.6.1136 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 53(6):1136-1141, 2012 Practice Patterns of Korean Urologists for Screening and Managing Prostate
More informationTitle: Prostate Specific Antigen (PSA) for Prostate Cancer Screening: A Clinical Review
Title: Prostate Specific Antigen (PSA) for Prostate Cancer Screening: A Clinical Review Date: November 26, 2007 Context and policy issues: Prostate cancer is the most common tumor in men, and is one of
More informationJMSCR Vol 05 Issue 07 Page July 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i7.16 Original Article Role of Serum PSA in
More informationAGE-SPECIFIC REFERENCE RANGES FOR SERUM PROSTATE-SPECIFIC ANTIGEN IN BLACK MEN. The New England Journal of Medicine
AGE-SPECIFIC REFERENCE RANGES FOR SERUM PROSTATE-SPECIFIC ANTIGEN IN BLACK MEN TED O. MORGAN, M.D., STEVEN J. JACOBSEN, M.D., PH.D., WILLIAM F. MCCARTHY, PH.D., DEBRA J. JACOBSON, M.S., DAVID G. MCLEOD,
More informationBJUI. Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer?
. JOURNAL COMPILATION 2010 BJU INTERNATIONAL Urological Oncology FOLLOW-UP OF MEN WITH AN ELEVATED PCA3 SCORE AND A NEGATIVE BIOPSY REMZI ET AL. BJUI BJU INTERNATIONAL Follow-up of men with an elevated
More informationOptimal Baseline Prostate-Specific Antigen Level to Distinguish Risk of Prostate Cancer in Healthy Men Between 40 and 69 Years of Age
ORIGINAL ARTICLE Oncology & Hematology http://dx.doi.org/.46/jkms..7..4 J Korean Med Sci ; 7: 4-45 Optimal Baseline Prostate-Specific Antigen Level to Distinguish Risk of Prostate Cancer in Healthy Men
More informationEvaluation of a new, rapid, qualitative, one-step PSA Test for prostate cancer screening: the PSA RapidScreen test
Evaluation of a new, rapid, qualitative, one-step PSA Test for prostate cancer screening: the PSA RapidScreen test R Miano 1 *, GO Mele 2, S Germani 1, P Bove 1, S Sansalone 1, PF Pugliese 2 & F Micali
More informationProspective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort
European Journal of Cancer (2012) 48, 1809 1815 Available at www.sciencedirect.com journal homepage: www.ejconline.com Prospective validation of a risk calculator which calculates the probability of a
More informationNIH Public Access Author Manuscript Cancer. Author manuscript; available in PMC 2010 March 1.
NIH Public Access Author Manuscript Published in final edited form as: Cancer. 2009 September 1; 115(17): 3879 3886. doi:10.1002/cncr.24447. Rational Approach to Implementation of PCA3 into Clinical Care
More informationAssociation of [ 2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer
Association of [ 2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer Jeffrey J. Tosoian,*, Stacy Loeb,*, Zhaoyong Feng, Sumit Isharwal, Patricia Landis, Debra J. Elliot,
More information